| Autor: |
Mancuso R; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy., Agostini S; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy., Citterio LA; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy., Chiarini D; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy., Santangelo MA; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy., Clerici M; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy. |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccines [Vaccines (Basel)] 2022 Oct 01; Vol. 10 (10). Date of Electronic Publication: 2022 Oct 01. |
| DOI: |
10.3390/vaccines10101649 |
| Abstrakt: |
BNT162b2 (BioNTech/Pfizer) was the first SARS-CoV-2 mRNA vaccine approved by the European Medicines Agency. We monitored the long-term humoral responses of healthcare workers (HCWs) who received three vaccine doses. A total of 59 healthcare workers were studied: 47 were never SARS-CoV-2-infected (naïve-HCWs), and 12 (infected-HCWs) recovered from COVID-19 before the first vaccine. Serum and saliva were collected at baseline (before the first dose), just before the second dose, 1, 3, 6, and 9 months after the second dose, and 10 days after the third vaccine. SARS-CoV-2-specific IgG and IgA were evaluated in serum and saliva, respectively, and the presence of neutralizing antibodies (NAb) was analyzed in serum. SARS-CoV-2-specific IgG peaked one month after the second vaccine in naïve-HCWs but right before this timepoint in infected-HCWs. IgG titers significantly decreased during follow-up and at month 9 were still detectable in 50% of naïve-HCWs and 90% of infected-HCWs. NAb were significantly decreased 6 months after the second vaccine in naïve-HCWs and 9 months after this dose in infected-HCWs. Salivary SARS-CoV-2-specific IgA titers were significantly higher in infected-HCWs and were undetectable 9 months after the second vaccine in 43% of the naïve-HCWs alone. The third vaccine greatly increased humoral IgG and mucosal IgA in both groups. Two BNT162b2 doses induced strong systemic and humoral immune responses; to note, these responses weakened over time, although they are more prolonged in individuals who had recovered from COVID-19. The third vaccine dose quickly boosts systemic and mucosal humoral responses. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
